The Good Stuff:
BMS gets approval for new oncology drug (for breast cancer) Ixempra.
Abraxis gets cancer drugs approved.
J&J gets Doribax (for intra-abdominal and urinary tract infections) approved.
Bayer reports upbeat MS drug results.
Glaxo: new use of HIV drug Lexiva OK’d.
Say what? Viagra and other impotence drugs may be causing hearing loss??
Pfizer pulls the plug on Exubera, lets partner Nektar know after the press release.
Major job cuts at struggling Boston Scientific.
J&J‘s drug biz not growing as rapidly as has been typical. Here’s why.
Genentech posts “only” 22% year over year earnings growth. This is apparently considered a disappointment…
Byetta and acute pancreatitis: beware!
Pfizer and Wyeth report large charges in their earnings reports (buy Lilly has good numbers)
Speculation, gossip, other stuff:
Biogen hangs out a “For Sale” sign.
Pfizer jumps into Sermo, the physician networking site. Not everyone is thrilled.
Who is Pfizer going to buy up next? Genzyme? Everyone is hot on biotech acquisitions these days…